RAPP

Rapport Therapeutics, Inc.
CAPPED RATING

Rapport Therapeutics, Inc. (RAPP) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
F
Factor Score 0.6 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
C-
Factor Score 1.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -6.5
EV / EBITDA -7.0
Rev Growth YoY N/A
Gross Margin N/M
Price Return 3M -46.0%
Price Return 12M 3.9%
Catalyst Signal 0.00
Market Cap $1.6B
TTM Revenue $20.0M
Price / Sales 77.5
ROE -33.3%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) F (0.6) C+ (2.6) C- (1.9) C+ (2.6) C- (2.1)
2026-11-07 C+ (2.6) F (0.6) C+ (2.6) D+ (1.8) C+ (2.7) C- (2.1)
2026-10-31 C+ (2.6) F (0.6) C+ (2.8) C (2.3) C+ (2.7) C (2.2)
2026-10-24 C+ (2.6) F (0.6) C+ (2.7) C- (2.1) C+ (2.6) C- (2.1)
2026-10-17 C+ (2.6) F (0.5) C+ (2.7) C+ (2.6) C+ (2.6) C (2.2)
Page 1 of 4